EP3072898A1 - Homo- und heterodimere mimetische smac-verbindungen als apoptoseinduktoren - Google Patents

Homo- und heterodimere mimetische smac-verbindungen als apoptoseinduktoren Download PDF

Info

Publication number
EP3072898A1
EP3072898A1 EP16165611.1A EP16165611A EP3072898A1 EP 3072898 A1 EP3072898 A1 EP 3072898A1 EP 16165611 A EP16165611 A EP 16165611A EP 3072898 A1 EP3072898 A1 EP 3072898A1
Authority
EP
European Patent Office
Prior art keywords
alkyl
optionally substituted
hydrogen
compound
independently
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP16165611.1A
Other languages
English (en)
French (fr)
Inventor
Pierfausto Seneci
Laura Belvisi
Federica COSSU
Domenico Delia
Carmelo Drago
Daniele LECIS
Stefano Maiorana
Leonardo Pierpaolo Manzoni
Eloise Mastrangelo
Mario Milani De Mayo De Mari
Paola Maria Chiara PEREGO
Francesca Vasile
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Biontech SE
Original Assignee
Universita degli Studi di Milano
Fondazione IRCCS Istituto Nazionale dei Tumori
CISI SCARL
Fondazione Cariplo
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Universita degli Studi di Milano, Fondazione IRCCS Istituto Nazionale dei Tumori, CISI SCARL, Fondazione Cariplo filed Critical Universita degli Studi di Milano
Priority to EP16165611.1A priority Critical patent/EP3072898A1/de
Publication of EP3072898A1 publication Critical patent/EP3072898A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/07—Tetrapeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/06—Tripeptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0806—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/1008—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atoms, i.e. Gly, Ala
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/10—Tetrapeptides
    • C07K5/1002—Tetrapeptides with the first amino acid being neutral
    • C07K5/1005—Tetrapeptides with the first amino acid being neutral and aliphatic
    • C07K5/101—Tetrapeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Definitions

  • the present invention relates to conformationally constrained homo- and heterodimeric mimetics of Smac (Second mitochondria-derived activator of caspases) with function as inhibitors of Inhibitor of Apoptosis Proteins (IAPs).
  • Smac Synd mitochondria-derived activator of caspases
  • IAPs Inhibitor of Apoptosis Proteins
  • the invention also relates to the use of these compounds, alone or in combination with other active ingredients, in the treatment of cancer, wherein the induction of apoptotic cell death is beneficial.
  • Apoptosis is absolutely necessary for human development and survival, with millions of cells committing suicide daily as a way to prevent uncontrolled growth. Defects in apoptosis, together with amplified growth signals, often lead to cancer. Targeting apoptosis defects in cancer has a tremendous potential.
  • the first human apoptotic protein identified was BCL-2, as inhibitor of apoptosis, in 1984.
  • the role of caspases-proteases that act as the cell's direct executioners by cleaving other cellular proteins was revealed in humans beginning in 1993.
  • pro-apoptotic BCL-2 family members like BAX, disrupt mitochondria, causing the release of other proteins that lead to caspase release and cell death.
  • Activation of this so-called "intrinsic" apoptotic pathway is the goal of many of the new cancer drugs.
  • cancer therapies including chemotherapeutic agents, radiation, and immunotherapy, work by indirectly inducing apoptosis in cancer cells.
  • the inability of cancer cells to execute an apoptotic program due to defects in the normal apoptotic machinery is thus often associated with an increase in resistance to chemotherapy, radiation or immunotherapy-induced apoptosis.
  • the first class is the BCL-2 family of proteins.
  • Anti-Bcl-2 biologicals antisense, antibodies, etc.
  • obatoclax, gossypol, ABT-763 Two classes of central negative regulators of apoptosis have been identified.
  • the first class is the BCL-2 family of proteins.
  • Anti-Bcl-2 biologicals antisense, antibodies, etc.
  • obatoclax, gossypol, ABT-763 have also entered Phase II clinical trials for the same indications.
  • the second class of central negative regulators of apoptosis is the inhibitor of apoptosis proteins (IAPs).
  • IAPs potently suppress apoptosis induced by a large variety of apoptotic stimuli, including chemotherapeutic agents, radiation, and immunotherapy in cancer cells.
  • X-linked IAP is the most studied IAP family member, and one of the most potent inhibitors in suppressing apoptosis among all of the IAP members.
  • XIAP plays a key role in the negative regulation of apoptosis in both the death receptor-mediated and the mitochondria-mediated pathways.
  • XIAP functions as a potent endogenous apoptosis inhibitor by directly binding and potently inhibiting three members of the caspase family enzymes, caspase-3, -7, and -9.
  • XIAP contains three baculovirus inhibitor of apoptosis repeat (BIR) domains.
  • the third BIR domain (BIR3) selectively targets caspase-9, the initiator caspase in the mitochondrial pathway, whereas the linker region between BIR1 and BIR2 inhibits both caspase-3 and caspase-7. While binding to XIAP prevents the activation of all three caspases, it is apparent that the interaction with caspase-9 is the most critical for its inhibition of apoptosis. Because XIAP blocks apoptosis at the downstream effector phase, a point where multiple signalling pathways converge, strategies targeting XIAP may prove to be especially effective to overcome resistance of cancer cells to apoptosis.
  • IAP-1 and 2 cellular IAPs 1 and 2 (cIAP-1 and cIAP-2) were also identified and characterized as potent inhibitors in suppressing apoptosis via two distinct pathways. Direct caspase inhibition happens through binding to the same BIR domains as XIAP, but inhibition of TNF- ⁇ induced apoptosis and induction of non-canonical NF- ⁇ B activation is also observed.
  • both cIAP-1 and cIAP-2 are essential for maintaining this balance.
  • both cIAPs may play an important role in the control of angiogenesis and blood vessel homeostasis in several pathologies involving regeneration and tumorigenesis.
  • pan-IAP inhibitors as potent and effective pro-apoptotic agents in oncology.
  • Smac/DIABLO second mitochondria-derived activator of caspases
  • Smac/DIABLO second mitochondria-derived activator of caspases
  • Smac is synthesized with an N-terminal mitochondrial targeting sequence that is proteolytically removed during maturation to the mature polipeptide.
  • Smac was shown to directly interact with XIAP, cIAP-1, cIAP-2 and other IAPs, to disrupt their binding to caspases and facilitate caspases activation.
  • Smac is a potent endogenous inhibitor of XIAP.
  • Smac/DIABLO interacts with both the BIR2 and BIR3 domains of XIAP.
  • the crystal structure of Smac/DIABLO reveals that it forms a homodimer through a large, hydrophobic interface, and that homodimerization is essential for its binding to the BIR2, but not BIR3, domain of XIAP.
  • the four amino-terminal residues of Smac/DIABLO (Ala-Val-Pro-Ile, AVPI) make specific contact with a surface groove of the BIR2 and BIR3 domains, but not with the BIR1 domain, of XIAP.
  • the conserved tetrapeptide motif has remarkable homology to the IAP-interacting motif found in the p12 amino-terminal sequence of caspase-9 (Ala- Thr-Pro-Phe) and the Drosophila proteins Hid (Ala-Val-Pro-Phe), Reaper (Ala-Val-Ala-Phe) and Grim (Ala-Ile-Ala-Tyr).
  • Kd 0.4 ⁇ M
  • Object of the present invention is to provide new non-peptidic compounds and a process for their preparation.
  • Still another object of the present invention is to provide new non-peptidic compounds showing activity as inhibitors of those substances that act as inhibitors of Apoptosis Proteins (IAPs), thus being able to re-establish the spontaneous human apoptosis process.
  • IAPs Apoptosis Proteins
  • Additional object of the present invention is to overcome the intrinsic limitations of peptide-based IAP inhibitors by providing non-peptidic compounds.
  • Another object of the present invention is to provide non-peptide, homo- and heterodimeric small molecules able to mimic the binding of Smac to XIAP, to cIAP-1 and to cIAP-2.
  • linker 83 can be prepared according to Tetrahedron Lett. 1998, 39, 6277 ; Makromol. Chem. 1979, 180, 2539 . Details are given in the experimental section of this description.
  • heteroalkyl alkyl, alkenyl, alkynyl and aryl groups, respectively, wherein one or more carbon atoms are replaced by a heteroatom selected among O, S and N.
  • the alkyl, alkenyl, alkynyl groups can be linear or branched; such groups may be for example selected as methyl, ethyl, propyl, isopropyl, butyl, tert-butyl, ethenyl, propenyl, isopropenyl, butenyl, isobutenyl, hexenyl, ethynyl, propynyl, butynyl.
  • alkyl groups are lower alkyl groups, i.e. they have 1 to 6 carbon atoms and alkenyl and alkynyl groups are lower alkenyl and alkynyl groups, i.e. they have 2 to 6 carbon atoms.
  • the term "optionally substituted”, if not expressly defined, means that any substitution is possible, provided that the resulting molecule is chemically stable.
  • the expression “optionally substituted” means that the designated groups may be optionally substituted for instance by alkyl, cycloalkyl, optionally substituted aryl, alkylaryl, heteroaryl, alkylheteroaryl, OR 4 , SR 4 , NR 4 R 5 or COOR 4 .
  • a preferred embodiment is that where the optionally substituted alkyl, heteroalkyl, alkenyl, heteroalkenyl, alkynyl, heteroalkynyl, alkylaryl or alkylheteroaryl groups are substituted on the aliphatic chains by oxo or thioxo groups.
  • A is NH 2 or NH-Alkyl or -N(Alkyl) 2 .
  • B is an alkyl group, more preferably methyl, ethyl or an optionally substituted alkylaryl group, such as a benzyl group.
  • n is 2.
  • m is 1.
  • m is 2.
  • NR 4 is a NH, thus R 4 being preferably selected as hydrogen.
  • the compounds of the invention present some chiral carbons and therefore may exist in the form of racemates or diastereoisomers, all being encompassed by the scope of the invention.
  • the present invention relates to homodimeric compounds of formula (I) having the following stereochemical configuration wherein the substituents are as defined above and the wedge-shaped bonds indicate that the substituents are positioned above the plane.
  • the present invention relates to heterodimeric compounds of formula (II) having the following configuration wherein the substituents are as defined above and the wedge-shaped bonds indicate that the substituents are positioned above the plane.
  • Each of the above described compound can be obtained as such, as its saline form or as a pharmaceutically acceptable salt or a prodrug.
  • prodrug means that compounds of the invention are in the form of a precursor of the active ingredient, said precursor being metabolized, after administration, to the active compound of formula (I).
  • the compounds of this invention may be prepared using experimental methods known to those skilled in the art, and according to the methods and reactions described in details in the experimental section of the present description.
  • the compounds of formula (I) and (II) induce apoptosis as standalone treatments, and also potentiate the induction of apoptosis as a response to proapoptotic signals.
  • the compounds may sensitize cells to inducers of apoptosis, including cells that are resistant to these inducers.
  • These compounds can be used to induce or restore apoptosis in any disease that can be prevented, ameliorated or fully treated by induction or restoration of apoptosis.
  • the present invention also provides compositions and methods for targeting mammals characterized as overexpressing an IAP family protein member.
  • the diseased cells such as cancer cells
  • the cells operationally confirm to possess elevated expression levels of IAP proteins due to their entering the apoptosis program and dying in response to an inhibiting effective amount of a compound of the invention, such response being at least in part due to their IAP protein function-dependent survival.
  • the invention pertains to modulating an apoptosis associated state which is connected with one or more apoptosis modulators.
  • apoptosis modulating agents include, but are not limited to, Fas/CD95, TRAMP, TNF R1, DR1, DR2, DR3, DR4, DR5, DR6, FADD, RIP, TNFa, Fas ligand, TRAIL, antibodies to TRAILR1 or TRAILR2, Bcl-2, p53, BAX, BAD, Akt, CAD, PI3 kinase, PP1, and caspase proteins in general.
  • Preferred apoptosing modulators are inducers of apoptosis such as TNF or a TNF-related ligand, particularly a TRAMP ligand, a Fas/CD95 ligand, a TNFR-1 ligand, or TRAIL.
  • the compounds of formula (I) and (II) prevent or inhibit angiogenesis and disrupt blood vessel homeostasis during vascular development in pathological conditions as standalone treatments.
  • the present invention relates to the use of the compounds of formula for the preparation of medicaments to treat diseased cells, tissues, organs, or pathological conditions and/or disease states in an animal (for example, a mammalian subject including, but not limited to, humans and veterinary mammals), more specifically for the treatment and/or prophylaxis of cancer and related conditions, such as lymphoma, melanoma, glioma, glioblastoma, myeloma, insulinoma, hypercalcemia, leukaemia, neuroblastoma, sarcoma, polycythemia, thrombocytosis, Hodgkin's disease, macroglobulinemia; autoimmune diseases; inflammatory diseases; infections; hyperproliferative diseases; AIDS; neurodegenerative diseases; vascular diseases.
  • treated cancer cells are metastatic.
  • treated cancer cells are resistant to common anticancer agents.
  • Infections suitable for treatment with the compounds of the invention include, but are not limited to, infections caused by viruses, bacteria, fungi, mycoplasma, prions.
  • Endothelial cell-associated diseases suitable for treatment with the compounds of the invention include, but are not limited to, macular degeneration, rheumatoid arthritis, psoriasis, diabetic retinopathycomeal graft rejection, myocardial angiogenesis, telangiectasia, angiofibroma, wound granulation, atherosclerosis, scleroderma and hypertrophic scars.
  • the present invention relates to pharmaceutical compositions comprising at least one of the compounds of formula (I) and (II).
  • the present invention relates to combinations of an effective amount of a compound of formula (I) and (II) and at least one additional therapeutic agent (including, but not limited to, chemotherapeutics, apoptosis modulators, anti-angiogenetics, antimicrobials, antivirals, antifungals and anti-inflammatory agents).
  • additional therapeutic agent including, but not limited to, chemotherapeutics, apoptosis modulators, anti-angiogenetics, antimicrobials, antivirals, antifungals and anti-inflammatory agents.
  • anticancer agents are contemplated for use in the method of the present invention.
  • chemotherapeutic compounds and anticancer therapies suitable for co-administration with compounds of formula (I) and (II) are known to those skilled in the art.
  • anticancer agents comprise agents that induce or stimulate apoptosis. They include, but are not limited to, radiation therapies; TNF-related factors; kinase inhibitors; antisense molecules; antibodies; anti-estrogens; antiandrogens; COX-2 inhibitors; anti-inflammatory drugs; cancer chemotherapeutic drugs; cellular signalling molecules; ceramides and cytokines; staurosporine, and the like. Specific examples of anticancer agents suitable for co-administration with compounds of Formula (I) and (II) are known to those skilled in the art.
  • composition and methods of the present invention provide a compound of Formula (I) and (II) and at least one anti-hyperproliferative or antineoplastic agent selected from alkylating agents, antimetabolites, and natural products (for example, plant- and/or animal-derived compounds).
  • alkylating agents suitable for use in the present compositions and methods include, but are not limited to, nitrogen mustards; ethyleneimines and methylmelamines; alkyl sulfonates; nitrosoureas; triazenes.
  • alkylating agents suitable for co-administration with compounds of Formula (I) and (II) are known to those skilled in the art.
  • antimetabolites suitable for use in the present compositions and methods include, but are not limited to, folic acid analogues; pyrimidine analogues; purine analogues.
  • Specific examples of antimetabolites suitable for co-administration with compounds of Formula (I) and (II) are known to those skilled in the art.
  • chemotherapeutic agents suitable for use in the present compositions and methods include, but are not limited to, vinca alkaloids; epipodophyllotoxins; antibiotics; enzymes; biological response modifiers; platinum coordinating complexes; anthracenediones; methylhydrazine derivatives; adrenocortical suppressants; adrenocorticosteroids; progestins; estrogens; androgens; antiandrogens; gonadotropin-releasing hormone analogues.
  • Specific examples of chemotherapeutic agents suitable for co-administration with compounds of Formula (I) and (II) are known to those skilled in the art.
  • any oncolytic agent that is routinely used in a cancer therapy context finds use in the composition and methods of the present invention.
  • the U.S. FDA and international counterpart agencies to the U.S. FDA maintain formularies of oncolytic agents approved for use, whose listed members are for example suitable for co-administration with compounds of Formula (I and (II).
  • the "product labels" required on all approved chemotherapeutics describe approved indications, dosing information, toxicity data, and the like, for the agents.
  • anticancer agents and other therapeutic agents suitable, for example, to be co-administered or associated with the compounds according to formula (I) and (II) of the present invention those skilled in the art are referred to any number of instructive manuals including, but not limited to, the Physician's Desk Reference and to Goodman and Gilman's "Pharmaceutical Basis of Therapeutics" 11th Edition, Eds. Hardman et al., 2005 .
  • the present invention relates to a combination of an effective amount of a compound of formula (I) and (II) and at least one treatment for cancer, for instance, surgical intervention or radiotherapy.
  • the present invention also provides methods for administering a compound of formula (I) and (II) with radiation therapy.
  • the invention is not limited by the types, amounts, or delivery and administration systems used to deliver the therapeutic dose of radiation to an animal.
  • the source of radiation can be external or internal to the animal.
  • External radiation therapy is most common and involves directing a beam of high-energy radiation to a tumour site through the skin using, for instance, a linear accelerator.
  • Internal radiation therapy involves implanting a radiation-emitting source inside the body at or near the tumour site, including the use of delivery systems that specifically target cancer cells.
  • the animal may optionally receive radiosensitizers or radioprotectors. Radiosensitizers enhance the killing of tumour cells. Radioprotectors protect healthy tissues from the harmful effect of radiation.
  • Radiotherapies include ionizing/electromagnetic radiotherapy and particle beam radiation therapy.
  • the total dose of radiation administered to an animal is preferably about .01 Gray (Gy) to about 100 Gy. More preferably, about 10 Gy to about 65 Gy are administered during the course of the treatment. While in some embodiments a complete dose of radiation can be administered over the course of one day, the total dose is ideally fractionated and administered over several days. Desirably, radiotherapy is administered at intervals of at least about 3 days, in a period of 1 to 8 weeks. Accordingly, a daily dose of radiation will comprise approximately 1-5 Gy, and preferably 1-2 Gy. The daily dose of radiation should be sufficient to induce destruction of the targeted cells, but days of rest from therapy should be included. For example, radiation desirably is administered on 5 consecutive days, and not administered for 2 days, for each week of treatment, thereby allowing 2 days of rest per week. These exemplary radiotherapy administration schedules are not intended, however, to limit the present invention.
  • a compound of Formula (I) and (II) and one or more therapeutic or anticancer agents are administered to an animal under one or more of the following conditions: at different periodicities, at different durations, at different concentrations, by different administration routers, and so on.
  • the compound is administered prior to the therapeutic or anticancer agent, i. e. 0.5, 1, 2, 3, 4, 5, 10, 12, or 18 hours, 1, 2, 3, 4, 5, or 6 days, 1, 2, 3 or 4 weeks prior to the administration of the therapeutic or anticancer agent.
  • the compound is administered after the therapeutic or anticancer agent, i.e.
  • the compound and the therapeutic or anticancer agent are administered concurrently but on different schedules, i.e. the compound is administered daily while the therapeutic or anticancer agent is administered once a week, once every two weeks, once every three weeks, or once every four weeks. In other embodiments, the compound is administered once a week while the therapeutic or anticancer agent is administered daily, once a week, once every two weeks, once every three weeks, or once every four weeks.
  • compositions within the scope of this invention include all compositions wherein the compounds of the present invention are comprised in an amount which is effective to achieve its intended purpose. While individual needs vary, determination of optimal ranges of effective amounts of each component is within the skill of the art.
  • the compounds may be administered to mammals, and in particular humans, orally at a dose of 0.0025 to 50 mg/kg, or an equivalent amount of the pharmaceutically acceptable salt thereof, per day of the body weight of the mammal being treated for disorders responsive to induction or restoration of apoptosis.
  • a dose 0.0025 to 50 mg/kg, or an equivalent amount of the pharmaceutically acceptable salt thereof, per day of the body weight of the mammal being treated for disorders responsive to induction or restoration of apoptosis.
  • about 0.01 to about 10 mg/kg is orally administered to treat, ameliorate, or prevent such disorders.
  • the dose is generally one half of the oral dose.
  • the compound may be present at a concentration of about 0.01 to 100 mg per gram of carrier. In a preferred embodiment, the compound is present at a concentration of about 0.07-1.0 mg/mL, more preferably, about 0.1-0.5 mg/mL, most preferably, about 0.4 mg/mL.
  • the compounds of the invention may be administered as part of a pharmaceutical preparation containing suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the compounds into preparations which can be used pharmaceutically.
  • suitable pharmaceutically acceptable carriers comprising excipients and auxiliaries which facilitate processing of the compounds into preparations which can be used pharmaceutically.
  • the preparations particularly those preparations which can be administered orally or topically and which can be used for the preferred type of administration, such as tablets, dragées, slow release lozenges and capsules, mouth rinses and washes, gels, liquid suspensions, hair rinses, hair gels, shampoos and other preparations which can be administered rectally, such as suppositories, as well as suitable solutions for administration by injection, topically or orally, contain from about 0.01 to 99 percent, preferably from 0.25 to 75 percent of active compound(s), together with the excipient.
  • the compounds and pharmaceutical compositions thereof may be administered by any means that achieve their intended purpose.
  • administration may be by parenteral, subcutaneous, intravenous, intramuscular, intraperitoneal, transdermal, buccal, intratechal, intracranial, intranasal or topical routes.
  • administration may be by the oral route.
  • the dosage administered will be dependent upon the age, health, and weight of the recipient, kind of concerned treatment, if any, frequency of treatment, and the nature of the desired effect.
  • compositions of the present invention are manufactured in a manner which is itself known, for example, by means of conventional mixing, granulating, dragée-making, dissolving, or lyophilizing processes.
  • pharmaceutical preparations for oral use can be obtained by combining the active compounds with solid excipients, optionally grinding the resulting mixture and processing the mixture of granules, after adding suitable auxiliaries, if desired or necessary, to obtain tablets or dragée cores.
  • Suitable excipients are, in particular, filters such as saccharides, cellulose preparations and/or calcium phosphates, as well as binders as starch paste, using, for example, starch, gelatine, cellulose, and/or polyvinyl pyrrolidone.
  • disintegrating agents may be added such as the above mentioned starches, crosslinked polyvinyl pyrrolidone, agar, or alginic acid or a salt thereof.
  • Auxiliaries are, above all, flow-regulating agents and lubricants, for example, silica, talc, stearic acid or salts thereof, and/or polyethylene glycol.
  • Dragée cores are provided with suitable coatings which, if desired, are resistant to gastric juices. In order to produce coatings resistant to gastric juices, solutions of suitable cellulose are used.
  • Other pharmaceutical preparations which can be used orally include push-fit capsule made of gelatine, as well as soft, sealed capsules made of gelatine and a plasticizer such as glycerol or sorbitol.
  • the push-fit capsules can contain the active compounds in the form of granules which may be mixed with fillers, binders and/or lubricants and, optionally, stabilizers.
  • the active compounds are preferably dissolved or suspended in suitable liquids, such as fatty oils, or liquid paraffin.
  • suitable liquids such as fatty oils, or liquid paraffin.
  • stabilizers may be added.
  • Possible pharmaceutical preparations which can be used rectally include, for example, suppositories, which consist of a combination of one or more active compounds with a suppository base.
  • Suitable suppository bases are, for example, natural or synthetic triglycerides, or paraffin hydrocarbons.
  • Suitable formulations for parenteral administration include aqueous solutions of the active compounds in water-soluble form.
  • suspensions of the active compounds as appropriate oily injection suspensions may be administered.
  • Suitable lipophilic solvents or vehicles include fatty oils or synthetic fatty acid esters.
  • Aqueous injections may contain substances which increase the viscosity of the suspension, such as sorbitol and/or dextran.
  • the suspension may also contain stabilizers.
  • the topical compositions of this invention are formulated preferably as oils, creams, lotions, ointments and the like by choice of appropriate carriers.
  • Suitable carriers include vegetable or mineral oils, white soft paraffin, fats and high molecular weight alcohol.
  • the preferred carriers are those in which the active ingredient is soluble.
  • Creams are preferably formulated from a mixture of mineral oil, self-emulsifying beeswax and water in which mixture the active ingredient, dissolved in a small amount of an oil is admixed.
  • a typical example includes about 40 parts water, about 20 parts beeswax, about 40 parts mineral oil and about 1 part almond oil.
  • Ointments may be formulated by mixing a solution of the active ingredient in a vegetable oil with warm soft paraffin and allowing the mixture to cool.
  • a typical example of such an ointment includes about 30% almond oil and about 70% white soft paraffin by weight.
  • Lotions may be conveniently prepared by dissolving the active ingredient, in a suitable high molecular weight alcohol.
  • Intermediates 5 are the synthetic gateway to functionalized homodimeric and heterodimeric bivalent Smac mimetics.
  • Compound 3a was synthesized by the general procedure described above.
  • BiotageTM C 18 reverse phase eluant conditions from 90% H 2 O and 10% CH 3 CN to 100% CH 3 CN. Yield 90% (1.65 g, MW 344.17, 4.79 mmol) of pure 3a as an amorphous white solid.
  • Compound 4a was synthesized by the general procedure described above starting from compound 3a (1.65 g, 4.79 mmol) and N-Boc, N-Me ethylglycine.
  • BiotageTM C 18 reverse phase eluant conditions from 90% H 2 O and 10% CH 3 CN to 100% CH 3 CN. Yield 82 % (1.78 g, MW 455.55, 3.91 mmol) of pure 4a as an amorphous white solid.
  • Analytical characterization ⁇ D 20 ⁇ 88.2 (c 0.5, CHCl 3 ).
  • Compound 4b was synthesized by the general procedure described above starting from compound 3a (1. 65 g, 4.79 mmol) and N-Boc ethylglycine.
  • BiotageTM C 18 reverse phase eluant conditions from 90% H 2 O and 10% CH 3 CN to 100% CH 3 CN. Yield 70 % (1.48 g, MW 441.25, 3.35 mmol) of pure 4b as an amorphous white solid.
  • BiotageTM eluant conditions from 1% of MeOH and 99% of CH 2 Cl 2 to 10% of MeOH and 90% of CH 2 Cl 2 . Yield 93 % (64 mg, MW 685.87,0.093 mmol) of pure
  • BiotageTM eluant conditions from 1% of MeOH and 99% of CH 2 Cl 2 to 10% of MeOH and 90% of CH 2 Cl 2. Yield 87 % (57 mg, MW 657.35, 0.087 mmol) of pure 12b.
  • HOBt (1.2 equiv), HBTU (1.2 equiv) and Sym-collidine (2.0 equiv) were sequentially added to a stirred solution of azides 13 (1.0 equiv) and N-Boc protected aminoacids 14 (1.25 equiv) in dry DMF ( ⁇ 0.15 M concentration for 13) at 0 °C.
  • the reaction mixture was left stirring and monitored by LC-MS. After reaction completion, the mixture was diluted with EtOAc and sequentially washed with 5% aqueous citric acid, saturated aqueous sodium bicarbonate and brine. The organic layer was dried over Na 2 SO 4 , and then the solvent removed under reduced pressure. The residue was purified by BiotageTM flash chromatography.
  • Compound 15a was synthesized by the general procedure described above starting from 11-azido-3,6,9-trioxaundecan-1-amine 13a (110 mg, 0.503 mmol) and Boc-( S )-2-Phenylglycine 14a (158 mg, 0.630 mmol).
  • BiotageTM eluant conditions from 1% of MeOH and 99% of CH 2 Cl 2 to 10% of MeOH and 90% of CH 2 Cl 2 . Yield 74 % (167 mg, MW 451.53, 0.37 mmol) of pure 15a.
  • HOBt (1.2 equiv), HBTU (1.2 equiv) and sym-collidine (4.0 equiv) were sequentially added to a stirred solution of the crude residue (1.0 theoretical equiv) and compounds 5 (1.25 equiv) in dry DMF ( ⁇ 0.10 M concentration for 5) at 0 °C.
  • the reaction mixture was left stirring and monitored by LC-MS. After reaction completion, the mixture was diluted with EtOAc and washed with 5% aqueous citric acid, saturated aqueous sodium bicarbonate and brine. The organic layer was dried over Na 2 SO 4 , and then the solvent removed under reduced pressure. The residue was purified by BiotageTM flash chromatography.
  • Compound 16a was synthesized by the general procedure described above starting from compound 15a (95 mg, 0.27 mmol) and 5a (150 mg, 0.34 mmol).
  • BiotageTM eluant conditions from 1% of MeOH and 99% of CH 2 Cl 2 to 10% of MeOH and 90% of CH 2 Cl 2 . Yield 82 % (170 mg, MW 774.92, 0.220 mmol) of pure 16a.
  • BiotageTM C 18 reverse phase eluant conditions from 90% H 2 O (1% CH 3 COOH) and 10% CH 3 CN (1% CH 3 COOH) to 100% CH 3 CN (1% CH 3 COOH). Yield 98 % (162 mg, MW 748.95, 0.219 mmol) of pure 17a.
  • BiotageTM eluant conditions from 1% of MeOH and 99% of CH 2 Cl 2 to 10% of MeOH and 90% of CH 2 Cl 2 . Yield 74 % (67 mg, MW 829.01, 0.081 mmol) of pure 18a.
  • BiotageTM C 18 reverse phase eluant conditions from 90% H 2 O (1% CH 3 COOH) and 10% CH 3 CN (1% CH 3 COOH) to 100% CH 3 CN (1% CH 3 COOH). Yield 58 % (55 mg, MW 865.00, 0.064 mmol) of pure 19a.
  • reaction mixture was irradiated in a microwave reactor at 100°C for 30 min. After reaction completion, the solvent was removed under reduced pressure, the crude product was diluted with EtOAc and washed with water. The organic layer was dried over Na 2 SO 4 , and then the solvent removed under reduced pressure. Finally, the crude product was purified by BiotageTM flash chromatography.
  • BiotageTM eluant conditions from 1% of MeOH and 99% of CH 2 Cl 2 to 10% of MeOH and 90% of CH 2 Cl 2 . Yield 58 % (47 mg, MW 1431.77, 0.033 mmol) of pure 22a.
  • reaction mixture was stirred at room temperature and monitored by LC-MS. After reaction completion, the solution was diluted with CH 2 Cl 2 and then washed with a saturated aqueous solution of NH 4 Cl, then brine. The organic layer was dried over Na 2 SO 4 , and then the solvent removed under reduced pressure. The residue was purified by BiotageTM flash chromatography.
  • BiotageTM eluant conditions from 1% of MeOH and 99% of CH 2 Cl 2 to 10% of MeOH and 90% of CH 2 Cl 2 . Yield 45 % (21 mg, MW 1560.32, 0.0135 mmol) of pure 24a.
  • HOBt (2.4 equiv), HBTU (2.4 equiv) and Sym-collidine (4.0 equiv) were sequentially added at 0 °C to a stirred solution of commercially available diamines 25 (1.0 equiv) and N-Boc protected aminoacids 14 (2.5 equiv) in dry DMF ( ⁇ 0.15 M concentration for 25).
  • the reaction mixture was left stirring and monitored by LC-MS. After reaction completion, the mixture was diluted with EtOAc and sequentially washed with a saturated aqueous solution of NH 4 Cl, saturated aqueous solution of sodium bicarbonate, and brine. The organic layer was dried over Na 2 SO 4 , and then the solvent removed under reduced pressure. The residue was purified by BiotageTM flash chromatography.
  • Compound 26a was synthesized by the general procedure described above starting from 1,8-diaminooctane 25a (46 mg, 0.32 mmol) and Boc-( S )-2-Phenylglycine 14a (200 mg, 0.80 mmol).
  • BiotageTM eluant conditions from 1% of MeOH and 99% of CH 2 Cl 2 to 10% of MeOH and 90% of CH 2 Cl 2 . Yield 94 % (146 mg, MW 686.85,0.212 mmol) of pure 26d.
  • HOBt (2.4 equiv), HBTU (2.4 equiv) and Sym-collidine (4.0 equiv) were sequentially added to a stirred solution of the crude residue (1.0 theoretical equiv) and compounds 5 ( ⁇ 2.5 equiv) in dry DMF ( ⁇ 0.10 M concentration for 5) at 0 °C.
  • the reaction mixture was left stirring and monitored by LC-MS. After reaction completion, the mixture was diluted with EtOAc and sequentially washed with 5% aqueous citric acid, saturated aqueous sodium bicarbonate and brine. The organic layer was dried over Na 2 SO 4 , and then the solvent removed under reduced pressure. The residue was purified by BiotageTM flash chromatography.
  • Compound 27a was synthesized by the general procedure described above starting from compound 26a (34 mg, 0.08 mmol) and 5a (91 mg, 0.200 mmol).
  • BiotageTM eluant conditions from 1% of MeOH and 99% of CH 2 Cl 2 to 10% of MeOH and 90% of CH 2 Cl 2 . Yield 97 % (98 mg, MW 1257.59,0.078 mmol) of pure 27a.
  • BiotageTM eluant conditions from 1% of MeOH and 99% of CH 2 Cl 2 to 10% of MeOH and 90% of CH 2 Cl 2 . Yield 51 % (42 mg, MW 1352.63,0.031 mmol) of pure 27b.
  • BiotageTM eluant conditions from 1% of MeOH and 99% of CH 2 Cl 2 to 10% of MeOH and 90% of CH 2 Cl 2 . Yield 74 % (58 mg, MW 1391.69, 0.041 mmol) of pure 27c.
  • BiotageTM eluant conditions from 1% ofMeOH and 99% of CH 2 Cl 2 to 10% of MeOH and 90% of CH 2 Cl 2 . Yield 80 % (47 mg, MW 1333.64, 0.035 mmol) of pure 27d.
  • a 0.9 M aqueous solution of sodium ascorbate (0.55 equiv) and a 0.3 M aqueous solution of Cu(OAc) 2 (0.25 equiv) were sequentially added to a stirred solution of compounds 16 (1.0 equiv) and compounds 12 (1.0 equiv) in a 1:1 mixture of H 2 O/ t BuOH (final concentration of 16 ⁇ 0.05 M).
  • the reaction mixture was stirred overnight at room temperature and then the solvent was removed under reduced pressure. The residues were purified by BiotageTM flash chromatography.
  • Compound 31a was synthesized by the general procedure described above starting from compound 16a (44 mg, 0.057 mmol) and 12a (38 mg, 0.057 mmol).
  • BiotageTM eluant conditions from 1% of MeOH and 99% of CH 2 Cl 2 to 10% of MeOH and 90% of CH 2 Cl 2 . Yield 61 % (51 mg, MW 1460.79, 0.035 mmol) of pure 31a.
  • Compound 32a was synthesized by the general procedure described above starting from compound 18a (37 mg, 0.045 mmol) and 10a (29 mg, 0.045 mmol).
  • BiotageTM eluant conditions from 1% of MeOH and 99% of CH 2 Cl 2 to 10% of MeOH and 90% of CH 2 Cl 2 . Yield 80 % (52 mg, MW 1460.79, 0.036 mmol) of pure 32a.
  • HOBt (1.2 equiv), HBTU (1.2 equiv) and sym-collidine (4.0 equiv) were sequentially added to a stirred solution of compounds 19 (1.0 equiv) and compounds 11 (1.25 equiv) in dry DMF ( ⁇ 0.10 M concentration for 19) at 0 °C.
  • the reaction mixture was left stirring and monitored by LC-MS. After reaction completion, the mixture was diluted with EtOAc and washed with 5% aqueous citric acid, saturated aqueous sodium bicarbonate and brine. The organic layer was dried over Na 2 SO 4 , and then the solvent removed under reduced pressure. The residue was purified by BiotageTM flash chromatography.
  • Compound 33a was synthesized by the general procedure described above starting from compound 19a (54 mg, 0.063 mmol) and 11a (52 mg, 0.08 mmol).
  • BiotageTM eluant conditions from 1% of MeOH and 99% of CH 2 Cl 2 to 10% of MeOH and 90% of CH 2 Cl 2 . Yield 67 % (61 mg, MW 1457.77, 0.042 mmol) of pure 33a.
  • a pET28 vector (Novagen) with the cDNA coding for human XIAP BIR3 domain from residue 241 to 356 was used to transform Escherichia coli strain BL21. Protein expression was induced by adding isopropyl- ⁇ -D-thiogalactopyranoside (IPTG) to a final concentration of 1 mM and 100 ⁇ M zinc acetate (ZnAc) for 3 hours at 37 °C.
  • IPTG isopropyl- ⁇ -D-thiogalactopyranoside
  • ZnAc zinc acetate
  • Bacteria grown in LB medium plus kanamycin were harvested, resuspended in a buffer containing 50 mM Tris HCl pH 7.5,200 mM NaCl, 50 ⁇ M ZnAc and protease inhibitors, treated with 100 ⁇ g/ml lysozyme for 30 minutes in ice and then lysed by sonication. After elimination of debris by centrifugation, recombinant protein was purified using Ni-NTA (His-trap Ffcrude, Ge-Healthcare) followed by gel filtration (Superdex 200, Ge-Healthcare).
  • BIR3-His-tag was eluted with 250 mM imidazole and thereafter stored in 20 mM Tris pH 7.5, 200 mM NaCl, 50 ⁇ M ZnAc, and 10 mM Dithiothreitol.
  • Fluorescent polarization experiments were performed in black, flat-bottom 96-well microplates (PBI) and fluorescent polarization was measured by Ultra plate reader (Tecan). Fluorescent-labelled Smac peptide [AbuRPF-K(5-Fam)-NH 2 ] (FITC-SMAC) to a final concentration of 5 nM and increasing concentration of BIR3-His-tag from 0 to 20 ⁇ M were added to an assay buffer. The final volume in each well was 120 ⁇ l, with the assay buffer consisting of 100 mM potassium phosphate, pH 7.5; 100 ⁇ g/ml bovine y-globulin; 0.02% sodium azide. After a 15 min shaking, the plate was incubated for 3 hours at room temperature.
  • Fluorescence polarization was measured at an excitation and emission wavelenghts of 485 nm and 530 nm respectively.
  • the equilibrium binding graphs were constructed by plotting millipolarization units (mP) as function of the XIAP BIR3 concentration. Data were analyzed using Prism 4.0 software (Graphpad Software).
  • SMAC-mimic compounds were evaluated for their ability to displace FITC-SMAC probe from recombinant protein.
  • 5 mM of FITC-SMAC, XIAP BIR3-His-tag and serial dilutions of the SMAC-mimic compounds were added to each well to a final volume of 120 ⁇ l in the assay buffer described above.
  • the concentration of BIR3-His-tag used was 60 nM, able to bind more than 50% of the ligand in the saturation binding experiment.
  • fluorescent polarization was measured by Ultra plate reader (Tecan). All SMAC-mimics and the fluorescent peptide were stocked in DMSO.
  • IC 50 s of some examples are reported in the Table below, as an average value from three independent measurements, together with their standard deviation.
  • a pET28 vector (Novagen) with the cDNA coding for human XIAP from residue 124 to 356 (linker-BIR2-BIR3), coding for BIR2 and BIR3 domains and the linker region preceding BIR2, was used to transform Escherichia coli strain BL21. Protein expression was induced by adding isopropyl-p-D-thiogalactopyranoside (IPTG) to a final concentration of 1 mM and 100 ⁇ M zinc acetate (ZnAc) for 3 hours at 37 °C.
  • IPTG isopropyl-p-D-thiogalactopyranoside
  • ZnAc zinc acetate
  • Bacteria grown in LB medium plus kanamycin were harvested, resuspended in a buffer containing 50 mM Tris HCl pH 7.5, 200 mM NaCl, 50 ⁇ M ZnAc and protease inhibitors, treated with 100 ⁇ g/ml lysozyme for 30 minutes in ice and then lysed by sonication. After elimination of debris by centrifugation, recombinant protein was purified using Ni-NTA (His-trap Ffcrude, Ge-Healthcare) followed by gel filtration (Superdex 200, Ge-Healthcare).
  • linker-BIR2-BIR3-His-tag was eluted with 250 mM imidazole and thereafter stored in 20 mM Tris pH 7.5, 200 mM NaCl, 50 ⁇ M ZnAc, and 10 mM Dithiothreitol.
  • Fluorescent polarization experiments were performed in black, flat-bottom 96-well microplates (PBI) and fluorescent polarization was measured by Ultra plate reader (Tecan). Fluorescent-labelled dimeric Smac peptide SMAC-1F ( Nikolovska-Coleska et al., Analyt. Biochem. 374:87, 2008 ) to a final concentration of 1 nM and increasing concentration of linker-BIR2-BIR3-His-tag from 0 to 2 ⁇ M were added to an assay buffer. The final volume in each well was 120 ⁇ l, with the assay buffer consisting of 100 mM potassium phosphate, pH 7.5; 100 ⁇ g/ml bovine y-globulin; 0.02% sodium azide.
  • the equilibrium binding graphs were constructed by plotting millipolarization units (mP) as function of the XIAP linker-BIR2-BIR3 concentration. Data were analyzed using Prism 4.0 software (Graphpad Software).
  • SMAC-mimic compounds were evaluated for their ability to displace SMAC-1F probe from recombinant protein.
  • 1 nM of SMAC-1F, 3 nM of XIAP linker-BIR2-BIR3-His-tag and serial dilutions of the SMAC-mimic compounds (concentrations ranging from 2 ⁇ M to 0.2 nM) were added to each well to a final volume of 120 ⁇ l in the assay buffer described above. After being mixed for 15 minutes on a shaker and incubated 3 hours at room temperature, fluorescent polarization was measured by Ultra plate reader (Tecan). All SMAC-mimics and the fluorescent peptide were stocked in DMSO.
  • IC50s of some examples are reported in the Table below, as an average value from three independent measurements, together with their standard deviation.
  • the sequence coding for the 245-357 residues (XIAP-BIR3 structural homology numbering) constituting the cIAP1- and cIAP2-BIR3 domains were cloned in pET21(b) vector (Novagen) with a C-terminal 6xHis-tag.
  • the plasmids were used to transform Escherichia coli strain BL21(DE3).
  • the recombinant proteins were purified using Ni-NTA (His-trap FFcrude, Ge-Healthcare), followed by gel filtration (Superdex 200, Ge-Healthcare). The recombinant proteins were eluted in 20 mM Tris pH 8.0, 250 mM NaCl and 10 mM DTT. Aliquoted proteins were conserved at - 80°C.
  • the fluorescently-labelled Smac peptide (AbuRPF-K(5-Fam)-NH2, final concentration of 2 nM), and increasing concentrations of cIAP1- and cIAP2-BIR3 from 0 to 20 ⁇ M, were added to an assay buffer consisting of 100 mM potassium phosphate, pH 7.5, 100 ⁇ g/ml bovine y-globulin, 0.02% sodium azide. After shaking (15 min) the plate was incubated for 3 hours at room temperature. Fluorescence polarization was measured on an Ultra plate reader (Tecan), at excitation and emission wavelengths of 485 nm and 530 nm, respectively.
  • the equilibrium binding curves were drawn by plotting experimental data (millipolarization units, mP) as a function of recombinant concentration and the Kd values were evaluated as 4.8 ⁇ 0.6 nM for cIAPI-BIR3, and 23.6 ⁇ 1.6 nM for cIAP2-BIR3.All experiments were performed in black, flat-bottom 96-well microplates (Greiner bio-one). 4-substituted azabicyclo[5.3.0]alkane Smac-mimetics were evaluated for their ability to displace the fluorescent probe from recombinant protein.
  • Fluorescent probe (2 nM), cIAP1-BIR3 (10 nM) or cIAP2 (25 nM) and serial dilutions of 4-substituted azabicyclo[5.3.0]alkane Smac-mimetics (concentration ranging from 1 ⁇ M to 0.1 nM) were added to each well, to a final volume of 120 ⁇ l in the assay buffer described above. After 15 minutes mixing on a shaker, and 3 hours incubation at room temperature, fluorescent polarization was measured on the Ultra plate reader (Tecan).
  • Human cell lines MDA-MB-231 (breast epithelial adenocarcinoma), HL-60 (promieloblast cells) and PC-3 (prostate adenocarcinoma cells) were purchased from Istituto Zooprofilattico di Brescia ( www.bs.izs.it ). Reagents for cell culture were purchased from Sigma, unless otherwise indicated. Cells were grown on Plastic Petri dishes (Falcon) in RPMI 1640 medium supplemented with 2 mM L-glutamine, Penicillin (100 U/mL) /Streptomicin (100 ⁇ g/mL), 10% Fetal Bovine Serum. A subcultivation ratio of 1:4 was used. Cells were maintained at 37°C in an atmosphere of 95% air and 5% CO 2 .
  • Cells were seeded in 96-well flat bottom cell culture plates at a density of 5000 cells/well in 100 ⁇ L of culture medium. HL-60 cells were immediately stimulated with the indicated compounds for 96 hours in the incubator. MDA-MB-231 and PC-3 cells were allowed to adhere for 24 hours. prior to be exposed to the compounds for 96 hours in the incubator. Cells were exposed to the following concentrations of the compounds: 50 nM, 100 nM, 200 nM, 500 nM, 1 ⁇ M, 5 ⁇ M, 10 ⁇ M, 50 ⁇ M and 100 ⁇ M. Each point was done in triplicate. The cellular growth inhibitory effect of our compounds was evaluated using the MTT assay (Sigma).
  • MTT reagent solution 5 mg of MTT powder/mL diluted in Phosphate Buffer Salt saline solution
  • Phosphate Buffer Salt saline solution 10 ⁇ L of MTT reagent solution
  • cells were solubilized in Lysis Buffer (10% SDS/0,1% HCl in water, 100 ⁇ L for each well) for 24 hours at 37°C.
  • Lysis Buffer 10% SDS/0,1% HCl in water, 100 ⁇ L for each well
  • the absorbance was measured at 570 nm using a multiplate reader. Absorbance values were collected and IC 50 values were determined using GraphPad Prism5 software. The experiments were repeated twice.
  • MTT reagent solution 5 mg of MTT powder/ml diluted in Phosphate Buffer Salt saline solution
  • Phosphate Buffer Salt saline solution 10 mg of MTT powder/ml diluted in Phosphate Buffer Salt saline solution
  • cells were solubilized in Lysis Buffer (10% SDS/0,1% HCl in water, 100 ⁇ l for each well) for 24 hours at 37°C.
  • the absorbance was measured at 570 nm using a multiplate reader. Absorbance values were collected and IC 50 /IC 80 values were determined using GraphPad Prism5 software.
  • Ovarian tumor i.p. xenografts The IGROV-1 tumor was adapted to grow in the peritoneal cavity (i.p.) and maintained by serial i.p. passages of ascitic cells into healthy mice. In this tumor model, hemorrhagic ascites with diffuse peritoneal carcinomatosis develops and the animal eventually die.
  • 2.5 x 10 6 ascitic cells in 0.2 ml of saline were injected i.p. into mice. Locoregional administration was employed. In particular, treatments started 1 day after cell inoculum. 28a was delivered i.p.
  • MST median survival time
  • percent survivorship over time was estimated by the Kaplan-Meier product method and compared using the log-rank test.
  • Ovarian tumor subcutanous xenografts 7.4 Ovarian tumor subcutanous xenografts.
  • s.c. subcutaneous
  • tumor cells 5 x 10 6 cells/mouse
  • the tumor line was achieved by serial s.c. passages of fragments (about 2x2x6 mm) from regrowing tumors into healthy mice.
  • Groups of five mice bearing bilateral s.c. tumors were employed. Tumor fragments were implanted on day 0 and tumor growth was followed by biweekly measurements of tumor diameters with a Vernier caliper.
  • 28a was delivered i.p. and administered for 5 days a week for three weeks (qdx5/wx3w). Treatment started three days after tumor implant, when tumors were just palpable.
  • the toxicity of the drug treatment was determined as body weight loss and lethal toxicity. Deaths occurring in treated mice before the death of the first control mouse were ascribed to toxic effects. Student t test (two tailed) exact test was used for statistical comparison of tumor volumes in mice.
  • mice xenografted i.p. with IGROV-1 human ovarian carcinoma cells were injected i.p. with 28a or standard compound SM-164 both delivered qd4-5/wx2 at a dose of 5 mg/kg. Treatment started the day after tumor cell inoculation. Control mice were treated i.p. with saline when evaluating the antitumor activity of 28a or with vehicle when the effect of the standard was examined. Results are summarized in Table 1 and mice survival is shown in Figure 1. The i.p. delivery of 28a led to a significant increased survival time compared with controls (P ⁇ 0.05) with a T/C value of 180%. Under the same experimental conditions, the T/C value obtained using the standard was 164% (P ⁇ 0.05).
  • mice were xenografted s.c. with IGROV-1, a significant inhibition of tumor growth was observed with 28a admininistration (i.p., 5 mg/Kg, qdx5/wx3), the TVI being of 66% (Table 2, P ⁇ 0.05 vs controls).
  • 28a admininistration i.p., 5 mg/Kg, qdx5/wx3
  • the TVI being of 66% (Table 2, P ⁇ 0.05 vs controls).
  • the standard used at the same dose and with the same schedule as 28a did not display any antitumor effect.
  • the invention provides, in particular, the following:

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
EP16165611.1A 2012-02-20 2012-02-20 Homo- und heterodimere mimetische smac-verbindungen als apoptoseinduktoren Withdrawn EP3072898A1 (de)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP16165611.1A EP3072898A1 (de) 2012-02-20 2012-02-20 Homo- und heterodimere mimetische smac-verbindungen als apoptoseinduktoren

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP12865538.8A EP2817322B1 (de) 2012-02-20 2012-02-20 Homo- und heterodimere mimetische smac-verbindungen als apoptoseinduktoren
PCT/IB2012/000297 WO2013124701A2 (en) 2012-02-20 2012-02-20 New homo- and heterodimeric smac mimetic compounds as apoptosis inducers
EP16165611.1A EP3072898A1 (de) 2012-02-20 2012-02-20 Homo- und heterodimere mimetische smac-verbindungen als apoptoseinduktoren

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
EP12865538.8A Division EP2817322B1 (de) 2012-02-20 2012-02-20 Homo- und heterodimere mimetische smac-verbindungen als apoptoseinduktoren

Publications (1)

Publication Number Publication Date
EP3072898A1 true EP3072898A1 (de) 2016-09-28

Family

ID=48783275

Family Applications (2)

Application Number Title Priority Date Filing Date
EP12865538.8A Active EP2817322B1 (de) 2012-02-20 2012-02-20 Homo- und heterodimere mimetische smac-verbindungen als apoptoseinduktoren
EP16165611.1A Withdrawn EP3072898A1 (de) 2012-02-20 2012-02-20 Homo- und heterodimere mimetische smac-verbindungen als apoptoseinduktoren

Family Applications Before (1)

Application Number Title Priority Date Filing Date
EP12865538.8A Active EP2817322B1 (de) 2012-02-20 2012-02-20 Homo- und heterodimere mimetische smac-verbindungen als apoptoseinduktoren

Country Status (4)

Country Link
US (2) US9321808B2 (de)
EP (2) EP2817322B1 (de)
ES (1) ES2572606T3 (de)
WO (1) WO2013124701A2 (de)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10347710B4 (de) 2003-10-14 2006-03-30 Johannes-Gutenberg-Universität Mainz Rekombinante Impfstoffe und deren Verwendung
DE102005046490A1 (de) 2005-09-28 2007-03-29 Johannes-Gutenberg-Universität Mainz Modifikationen von RNA, die zu einer erhöhten Transkriptstabilität und Translationseffizienz führen
NZ730355A (en) 2011-05-24 2022-10-28 Tron Translationale Onkologie An Der Univ Der Johannes Gutenberg Univ Mainz Gemeinnuetzige Gmbh Individualized vaccines for cancer
WO2013143555A1 (en) 2012-03-26 2013-10-03 Biontech Ag Rna formulation for immunotherapy
WO2014082729A1 (en) 2012-11-28 2014-06-05 Biontech Ag Individualized vaccines for cancer
WO2014180490A1 (en) 2013-05-10 2014-11-13 Biontech Ag Predicting immunogenicity of t cell epitopes
WO2015109391A1 (en) 2014-01-24 2015-07-30 Children's Hospital Of Eastern Ontario Research Institute Inc. Smc combination therapy for the treatment of cancer
WO2016045732A1 (en) 2014-09-25 2016-03-31 Biontech Rna Pharmaceuticals Gmbh Stable formulations of lipids and liposomes
WO2016128060A1 (en) 2015-02-12 2016-08-18 Biontech Ag Predicting t cell epitopes useful for vaccination
WO2017059902A1 (en) 2015-10-07 2017-04-13 Biontech Rna Pharmaceuticals Gmbh 3' utr sequences for stabilization of rna
US10653904B2 (en) 2017-12-02 2020-05-19 M-Fire Holdings, Llc Methods of suppressing wild fires raging across regions of land in the direction of prevailing winds by forming anti-fire (AF) chemical fire-breaking systems using environmentally clean anti-fire (AF) liquid spray applied using GPS-tracking techniques
US11865394B2 (en) 2017-12-03 2024-01-09 Mighty Fire Breaker Llc Environmentally-clean biodegradable water-based concentrates for producing fire inhibiting and fire extinguishing liquids for fighting class A and class B fires
US11865390B2 (en) 2017-12-03 2024-01-09 Mighty Fire Breaker Llc Environmentally-clean water-based fire inhibiting biochemical compositions, and methods of and apparatus for applying the same to protect property against wildfire
US11826592B2 (en) 2018-01-09 2023-11-28 Mighty Fire Breaker Llc Process of forming strategic chemical-type wildfire breaks on ground surfaces to proactively prevent fire ignition and flame spread, and reduce the production of smoke in the presence of a wild fire
US11911643B2 (en) 2021-02-04 2024-02-27 Mighty Fire Breaker Llc Environmentally-clean fire inhibiting and extinguishing compositions and products for sorbing flammable liquids while inhibiting ignition and extinguishing fire

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009060292A2 (en) * 2007-11-09 2009-05-14 Universita'degli Studi Di Milano Smac mimetic compounds as apoptosis inducers

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009060292A2 (en) * 2007-11-09 2009-05-14 Universita'degli Studi Di Milano Smac mimetic compounds as apoptosis inducers

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
"Goodman and Gilman's ''Pharmaceutical Basis of Therapeutics", 2005
BENARD ET AL., CANCER RES., vol. 45, 1985, pages 4970
MAKROMOL. CHEM., vol. 180, 1979, pages 2539
NIKOLOVSKA-COLESKA ET AL., ANALYT. BIOCHEM., vol. 374, 2008, pages 87
S. WANG ET AL., J. AM. CHEM. SOC., vol. 129, 2007, pages 15279
TETRAHEDRON LETT., vol. 39, 1998, pages 6277

Also Published As

Publication number Publication date
EP2817322B1 (de) 2016-04-20
US9730976B2 (en) 2017-08-15
US20150119342A1 (en) 2015-04-30
US20160317605A1 (en) 2016-11-03
ES2572606T3 (es) 2016-06-01
WO2013124701A3 (en) 2013-10-31
EP2817322A2 (de) 2014-12-31
US9321808B2 (en) 2016-04-26
WO2013124701A2 (en) 2013-08-29

Similar Documents

Publication Publication Date Title
EP2817322B1 (de) Homo- und heterodimere mimetische smac-verbindungen als apoptoseinduktoren
US8609685B2 (en) SMAC mimetic compounds as apoptosis inducers
JP6871310B2 (ja) ジペプチド及びトリペプチドエポキシケトンプロテアーゼ阻害剤
JP4954983B2 (ja) Ｂｉｒドメイン結合化合物
JP5419685B2 (ja) Ｉａｐｂｉｒドメイン結合タンパク質
CN1839139B (zh) 蛋白酶体抑制剂及其使用方法
KR20240019867A (ko) Tlr7/8 안타고니스트 및 이의 용도
JP2009529544A (ja) Ｉａｐのｂｉｒドメインに結合する化合物
CN117866042A (zh) 含有二硫化物的细胞穿透肽及其制备和使用方法
US20110021544A1 (en) Hydrochloride salt of ((1s,2s,4r)-4--2-hydroxycyclopentyl)methyl sulfamate
MXPA06008095A (es) Mimeticos de smac conformacionalmente restringidos y sus usos.
BRPI0617751A2 (pt) compostos de ligação do domìnio iap bir
KR20130086520A (ko) 스피로시클릭 화합물 및 이들의 치료제 및 진단 프로브로서 용도
FR2974576A1 (fr) Derives de n-[(1h-pyrazol-1-yl)aryl]-1h-indole ou 1h- indazole-3-carboxamide, leur preparation et leurs applications en therapeutique
EP3127912B1 (de) Mit heterocyclen konstruierte tripeptid-epoxyketonverbindungen sowie herstellungsverfahren und verwendung davon
KR20120046162A (ko) 2,3-디히드로-1ｈ-인덴 화합물 및 이의 암치료 용도
CA3080617A1 (en) Polypeptide conjugates for intracellular delivery of stapled peptides
EP4021473A1 (de) Geheftete beta-catenin-liganden
CA2930032A1 (en) Macrocyclic compounds for inhibition of inhibitors of apoptosis
WO2022103411A1 (en) 1-(2-(4-cyclopropyl-1h-1,2,3-triazol-1-yl)acetyl)-4-hydroxy-n-(benzyl)pyrrolidin e-2-carboxamide derivatives as vhl inhibitors for the treatment of anemia and cancer
CN110183471B (zh) 一种哌嗪类衍生物及制备方法及应用
CN115340527A (zh) 一种bcl-xl抑制剂及其制备方法和用途
MX2008005477A (en) Iap bir domain binding compounds

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

AC Divisional application: reference to earlier application

Ref document number: 2817322

Country of ref document: EP

Kind code of ref document: P

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR

RIN1 Information on inventor provided before grant (corrected)

Inventor name: SENECI, PIERFAUSTO

Inventor name: DELIA, DOMENICO

Inventor name: LECIS, DANIELE

Inventor name: MASTRANGELO, ELOISE

Inventor name: MANZONI, LEONARDO, PIERPAOLO

Inventor name: MILANI DE MAYO DE MARI, MARIO

Inventor name: PEREGO, PAOLA MARIA CHIARA

Inventor name: DRAGO, CARMELO

Inventor name: COSSU, FEDERICA

Inventor name: VASILE, FRANCESCA

Inventor name: MAIORANA, STEFANO

Inventor name: BELVISI, LAURA

RIN1 Information on inventor provided before grant (corrected)

Inventor name: PEREGO, PAOLA MARIA CHIARA

Inventor name: COSSU, FEDERICA

Inventor name: SENECI, PIERFAUSTO

Inventor name: VASILE, FRANCESCA

Inventor name: DRAGO, CARMELO

Inventor name: BELVISI, LAURA

Inventor name: MILANI DE MAYO DE MARI, MARIO

Inventor name: LECIS, DANIELE

Inventor name: MAIORANA, STEFANO

Inventor name: DELIA, DOMENICO

Inventor name: MANZONI, LEONARDO, PIERPAOLO

Inventor name: MASTRANGELO, ELOISE

RIN1 Information on inventor provided before grant (corrected)

Inventor name: DELIA, DOMENICO

Inventor name: LECIS, DANIELE

Inventor name: MILANI DE MAYO DE MARI, MARIO

Inventor name: SENECI, PIERFAUSTO

Inventor name: DRAGO, CARMELO

Inventor name: MASTRANGELO, ELOISE

Inventor name: BELVISI, LAURA

Inventor name: MANZONI, LEONARDO, PIERPAOLO

Inventor name: PEREGO, PAOLA MARIA CHIARA

Inventor name: MAIORANA, STEFANO

Inventor name: COSSU, FEDERICA

Inventor name: VASILE, FRANCESCA

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: BIONTECH AG

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20170329